Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a third-quarter FDA submission.
Celcuity said a combination regimen with its experimental drug gedatolisib doubled patients’ likelihood of survival without disease progression or death in a late-stage breast cancer …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
What's Going On With Celcuity Stock On Tuesday? - Celcuity (NASDAQ:CELC)
Biotech Plummets On Cancer Disappointment. What Happened?
More Data Support Trodelvy-Keytruda Combo in Triple-Negative Breast Cancer
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.
Celcuity expands VIKTORIA-2 to endocrine-sensitive breast cancer patients and advances injectable gedatolisib formulation.
Celcuity stock crashed Tuesday on disappointing results for its three-drug approach to advanced breast cancer.
ASCENT-04 analysis finds PFS2 advantage as an indicator of long-term clinical benefit
The FDA has approved the TROP2-directed ADC Datroway as a first-line option for triple-negative breast cancer, giving Daiichi…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
